Drugs / DAY301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06752681 | Nov 2024 → Dec 2027 expected | — | Day One Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAY301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752681 ↗ |
| Route | Intravenous | “DAY301 will be administered as IV infusion” NCT06752681 ↗ |
| Target | PTK7 | “PTK7-directed antibody-drug conjugate” NCT06752681 ↗ |